Detalhe da pesquisa
1.
Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
Int J Cardiol
; 398: 131598, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979789